open access

Vol 64, No 4 (2013)
Original papers
Published online: 2013-09-03
Submitted: 2013-09-03
Accepted: 2013-09-03
Get Citation

The role of Insulin-like Growth Factor 1, Receptor Activator for Nuclear Factor κB ligand — Osteoprotegerin system, Interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood

Anna Wędrychowicz, Krystyna Sztefko, Marcin Majka, Mariusz Z. Ratajczak
DOI: 10.5603/EP.2013.0001
·
Endokrynologia Polska 2013;64(4):248-254.

open access

Vol 64, No 4 (2013)
Original papers
Published online: 2013-09-03
Submitted: 2013-09-03
Accepted: 2013-09-03

Abstract

Introduction: Bone disorders observed commonly after haematopoietic stem cells transplantation (HSCT) can be caused by several factors,but their detailed pathomechanism is still not well known, especially in childhood.The aim of this study was to evaluate: IGF-I, RANKL-OPG system, IL-6, and IL1β levels and their association with bone mineral density(BMD) in children and adolescents after HSCT.

Material and methods: Thirty five patients after allogeneic (N = 21) and autologous (N = 14) HSCT, mean age 8.48 ± 5.18 years, wereincluded in the study. Blood samples were taken before HSCT, on the transplantation day, three and six months after HSCT, then eachyear after HSCT for 2–8 years. RANKL, OPG, and IL-1β, IGF-1, and IL-6 were measured by immunochemistry. Total BMD was evaluatedsix months after HSCT using dual energy X-ray absorptiometry, then annually.

Results: All Z-core values for BMD were negative in all patients. It was significantly higher in patients after auto HSCT than after allo HSCT.Serum levels of IGF-1 and IL-6 significantly changed after HSCT. IGF-I levels started to increase in the second year after transplantation.IL-6 increased up to 12 months after transplantation. Dynamic although not significant changes of OPG and RANKL levels were observedafter HSCT. RANKL and IGF-1 values correlated with BMD. IL-6 correlated positively with IL-1β but both did not correlate with BMD.

Conclusions: Our data indicates that factors influencing bone remodelling change dynamically in the post-transplantation period.It suggests that serum RANKL and IGF-1 levels could be markers of bone metabolism after HSCT in paediatric patients.

Abstract

Introduction: Bone disorders observed commonly after haematopoietic stem cells transplantation (HSCT) can be caused by several factors,but their detailed pathomechanism is still not well known, especially in childhood.The aim of this study was to evaluate: IGF-I, RANKL-OPG system, IL-6, and IL1β levels and their association with bone mineral density(BMD) in children and adolescents after HSCT.

Material and methods: Thirty five patients after allogeneic (N = 21) and autologous (N = 14) HSCT, mean age 8.48 ± 5.18 years, wereincluded in the study. Blood samples were taken before HSCT, on the transplantation day, three and six months after HSCT, then eachyear after HSCT for 2–8 years. RANKL, OPG, and IL-1β, IGF-1, and IL-6 were measured by immunochemistry. Total BMD was evaluatedsix months after HSCT using dual energy X-ray absorptiometry, then annually.

Results: All Z-core values for BMD were negative in all patients. It was significantly higher in patients after auto HSCT than after allo HSCT.Serum levels of IGF-1 and IL-6 significantly changed after HSCT. IGF-I levels started to increase in the second year after transplantation.IL-6 increased up to 12 months after transplantation. Dynamic although not significant changes of OPG and RANKL levels were observedafter HSCT. RANKL and IGF-1 values correlated with BMD. IL-6 correlated positively with IL-1β but both did not correlate with BMD.

Conclusions: Our data indicates that factors influencing bone remodelling change dynamically in the post-transplantation period.It suggests that serum RANKL and IGF-1 levels could be markers of bone metabolism after HSCT in paediatric patients.

Get Citation

Keywords

RANKL-OPG system, IGF-1, interleukins, post-transplantation bone metabolic disease, children and adolescents

About this article
Title

The role of Insulin-like Growth Factor 1, Receptor Activator for Nuclear Factor κB ligand — Osteoprotegerin system, Interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood

Journal

Endokrynologia Polska

Issue

Vol 64, No 4 (2013)

Pages

248-254

Published online

2013-09-03

DOI

10.5603/EP.2013.0001

Bibliographic record

Endokrynologia Polska 2013;64(4):248-254.

Keywords

RANKL-OPG system
IGF-1
interleukins
post-transplantation bone metabolic disease
children and adolescents

Authors

Anna Wędrychowicz
Krystyna Sztefko
Marcin Majka
Mariusz Z. Ratajczak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl